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Abstract	21	
Erythropoietin	(EPO)	rapidly	decreases	on	return	from	chronic	altitude	exposure.	Acute	hypoxia	may	22	
provide	an	additional	stimulus	to	prevent	this	decline	in	EPO.	Optimal	normobaric	hypoxic	exposure	23	
has	not	been	established;	therefore,	investigation	of	methods	eliciting	the	greatest	response,	whilst	24	
not	causing	any	addition	stress	is	required.	Eight	physically	active	males	(age	27	±	4	yrs,	body	mass	25	
77.5	 ±	 9.0	 kg,	 height	 179	 ±	 6	 cm)	 attended	 the	 laboratory	 on	 four	 separate	 occasions,	 in	 a	26	
randomised	 order,	 and	 rested	 passively	 in	 a	 hypoxic	 chamber	 for	 2	 h	 whilst	 exposed	 to	 four	27	
simulated	altitudes	[FiO2:	0.209	(SL),	FiO2:	~0.135	(3,600	m),	FiO2:	~0.125	(4,200	m)	and	FiO2:	~0.115	28	
(4,800	m)].	Venous	blood	samples	were	drawn	immediately	pre-exposure	and	then	at	1,	2,	4,	6	and	8	29	
h	 to	 assess	 changes	 in	 blood	 plasma	 erythropoietin	 concentration	 ([EPO]),	 interleukin-6	30	
concentration	 (IL-6)	 and	 tumor	 necrosis	 factor	 alpha	 concentration	 (TNFα).	 During	 4,200	 m	 and	31	
4,800	m	[EPO]	 increased	from	5.9	±	1.5	to	8.1	±	1.5	mUmL-1	(P	=	0.009)	and	6.0	±	1.4	to	8.9	±	2.0	32	
mUmL-1	(P	=	0.037),	respectively,	with	the	mean	increase	in	[EPO]	peaking	at	4h	(2h	post-exposure).	33	
Results	 indicate	 there	 were	 no	 differences	 found	 in	 IL-6	 or	 TNFα	 during	 or	 post-exposure.	 An	34	
increase	in	endogenous	[EPO]	was	found	two	hours	post-hypoxic	exposure	as	result	of	two	hours	of	35	
normobaric	hypoxia,	equivalent	to	4,200	m	and	above.	There	was	no	dose-response	relationship	in	36	
[EPO]	between	the	severity	of	simulated	hypoxia.		37	
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Introduction	1	
Exercise	performance	and	haematological	responses	have	been	shown	to	be	variable	in	response	to	2	
altitude	 exposures	 (Chapman	 et	 al.	 1998;	 Chapman	 2013).	 Practitioners	 and	 coaches	 should	3	
therefore	 consider	 individualising	 an	 athlete’s	 post-altitude	 training	 strategy	 in	 order	 to	 fully	4	
optimise	the	benefits	of	the	camp.	Elite	coach,	Dick	(1992),	discussed	training	at	altitude	in	practice	5	
and	 suggested	 that	on	 return	 from	altitude,	 time	was	needed	 to	 reach	a	 stage	were	performance	6	
shows	a	clear	 sign	of	benefit.	Although	 these	assumptions	were	based	upon	 the	 training	 status	of	7	
the	 athlete,	 there	 is	 haematological	 evidence	 to	 suggest	 there	 is	 a	 ‘re-acclimatisation’	 that	 occurs	8	
when	 returning	 to	 sea	 level	 from	 altitude.	 Garvican	 et	 al.	 (2012)	 observed	 a	 1.5%	 decrease	 in	9	
tHbmass	within	3	days	of	decent	from	a	3	week	natural	altitude	training	camp,	which	persisted	when	10	
measured	10	days	after	decent	and	Pottgiesser	et	al.	(2012)	found	that	9	days	after	completing	at	26	11	
day	simulated	altitude	training	camp	there	was	a	3.0%	decrease	in	tHbmass.	Brugniaux	et	al.	(2006)	12	
and	Heinicke	et	al.	(2005)	both	found	tHbmass	in	increased	after	3	days	at	sea	level	but	returned	to	13	
baseline	levels	after	16	and	15	days,	respectively.	14	
Prommer	 et	 al.	 (2009)	 found	 that	when	natural	 altitude	dwellers	 reside	 at	 sea	 level	 for	 sustained	15	
durations,	a	reduction	in	tHbmass	occurs.	The	study	found	tHbmass	remained	stable	within	the	first	16	
2	weeks	at	sea	level	followed	by	a	reduction	of	~2%	per	week	before	levelling	off	around	5-6	weeks	17	
post-altitude.	 The	 reduction	 in	 tHbmass	 was	 attributed	 to	 transiently	 suppressed	 erythropoietin	18	
(EPO)	as	a	result	of	returning	to	a	normoxic	environment	(Prommer	et	al.	2010).	The	removal	of	the	19	
altitude	 stimulus	 appear	 to	 result	 in	 a	 ‘re-acclimatization’	 to	 sea	 level	 (Garvican	 et	 al.	 2012).	20	
Chapman	et	al.	(2014)	stated	that,	if	an	athlete	completes	a	4	week	altitude	training	camp,	followed	21	
by	a	short	time	(~7–14	days)	at	sea	level	to	compete,	returning	to	altitude	even	for	a	short	time	may	22	
mitigate	or	delay	these	effects	by	re-establishing	EPO	levels	again.	23	
Brief	periods	of	severe	hypoxia	have	been	suggested	as	a	potential	method	to	prevent	the	sudden	24	
decrease	 in	 EPO	 (Pottgiesser	 et	 al.	 2012).	 This	 in	 turn	 would	 preserve	 the	 haematological	25	
acclimatisation	 response	 for	 a	 longer	 time,	 thereby	 expanding	 the	window	 for	 endurance	 training	26	
and	 optimal	 competition	 racing	 (Chapman	 et	 al.	 2014).	 Figure	 1	 illustrates	 the	 previous	27	
investigations	that	have	demonstrated	an	increase	in	EPO	as	a	result	of	exposures	lasting	5	minutes	28	
to	5.5	hours	(Eckardt	et	al.	1989;	Knaupp	et	al.	1992;	Rodríguez	et	al.	2000;	Ge	et	al.	2002;	Niess	et	29	
al.	 2004;	 Friedmann	 et	 al.	 2005;	MacKenzie	 et	 al.	 2008;	Wahl	 et	 al.	 2013).	 The	 chart	 bubble	 size	30	
represents	 the	magnitude	of	EPO	production	 in	 response	 to	exposure	 time	and	simulated	altitude	31	
(i.e.	 the	 larger	 the	 bubble,	 the	 greater	 the	 production	 of	 EPO).	 Collectively	 these	 findings	 suggest	32	
that	a	minimum	time	period	of	two	hours	at	an	altitude	of	>2,500	m	elicit	a	significant	 increase	 in	33	
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EPO;	however,	differing	methods	(hypobaric	vs.	normobaric),	physical	status	(rest	vs.	exercise)	and	1	
timing	of	blood	sampling	have	been	investigated.		2	
Stray-Gundersen	 et	 al.	 (2001)	 believed	 that	 when	 athletes	 attend	 altitude	 training	 camps	 it	 is	3	
possible	that	the	presence	of	injury	or	infection,	and	therefore	pro-inflammatory	cytokines	(such	as	4	
IL-6	and	TNFα),	could	impair	the	erythropoietic	response	to	altitude	(Faquin	et	al.	1992;	Jelkmann	et	5	
al.	1992).	Hypoxia	is	a	stressor	that	alters	homeostasis	(subsequent	to	a	reduction	in	arterial	oxygen	6	
(O2)	saturation)	and	may	result	in	an	inflammatory	response	(Mazzeo	et	al.	2013).	Previous	research	7	
has	found	that	in	persons	with	acute	mountain	sickness,	levels	of	interleukin-6	(IL-6)	and	C-reactive	8	
protein	(CRP)	were	increased	after	3	nights	at	elevations	higher	than	3400	m	(Hartmann	et	al.	2000)	9	
and	IL-6	was	elevated	after	12	nights	at	4,300	m	(Mazzeo	et	al.	2013).	Conversely,	Schobersberger	et	10	
al.	(2004)	found	in	clinical	trials	of	individuals	with	metabolic	syndrome,	there	were	no	differences	in	11	
IL-6	or	tumor	necrosis	factor-α	(TNFα)	after	a	3-week	sojourn	(living	and	hiking)	at	moderate	altitude	12	
(1,700	–	2,500	m).	Consequently,	if	additional	hypoxic	exposures	are	to	be	considered	post-altitude	13	
training	then	the	role	of	pro-inflammatory	cytokines	and	EPO	production	should	be	investigated.	14	
Altitude	 training	 is	 a	 common	 practice	 undertaken	 by	 endurance	 athletes	 in	 pursuit	 of	 an	15	
enhancement	 of	 subsequent	 sea	 level	 performance	 (Fudge	 et	 al.	 2012),	 however,	 identifying	 the	16	
best	 time	to	return	to	sea	 level	prior	 to	a	major	competition	to	optimise	the	haematological	gains	17	
remains	a	question	(Chapman	et	al.	2014).	A	minimum	exposure	of	two	hours	is	required	to	elicit	an	18	
increase	in	EPO;	however,	less	is	understood	about	the	effect	of	a	two	hour	exposure	of	normobaric	19	
hypoxia	on	EPO	and	the	 time	course	of	 this	 response.	Furthermore,	 the	 response	of	 inflammatory	20	
cytokines	to	differing	levels	of	hypoxia	in	healthy	individuals	is	unclear.	The	aim	of	this	study	was	to	21	
establish	the	dose-response	relationship	of	EPO,	alongside	markers	of	 inflammation	IL-6	and	TNFα,	22	
during	 and	 following	 two	 hour	 exposures	 of	 normobaric	 hypoxia	 with	 the	 intention	 of	mitigating	23	
neocytolysis.	We	 hypothesized	 that	 [EPO]	would	 increase	 following	 two	 hour	 normobaric	 hypoxic	24	
exposure,	and	the	increase	would	be	in	accordance	with	the	severity	of	simulated	altitude.	Secondly,	25	
basal	levels	of	pro-inflammatory	cytokines	would	inhibit	the	production	of	[EPO]	in	participants.		 	26	
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Method	1	
Participants	2	
Eight	physically	active,	Caucasian	males	participated	in	the	study	(see	table	1).	Participants	were	well	3	
trained,	 completing	 8	 ±	 3	 hours	 training	 per	 week.	 Institutional	 ethical	 approval	 was	 issued	 in	4	
accordance	 with	 the	 Helsinki	 declaration	 1975	 (revised	 2013)	 and	 participants	 provided	 written	5	
informed	 consent.	 Participants	 were	 non-smokers	 and	 had	 not	 been	 exposed	 to	 altitudes	 above	6	
2,000	 m	 in	 the	 preceding	 two	 months.	 Participants	 were	 instructed	 not	 to	 consume	 alcohol	 or	7	
caffeine	 during	 a	 period	 of	 at	 least	 24	 h	 immediately	 preceding	 each	 trial	 and	 maintained	 their	8	
normal	training	regimen	during	the	testing	period.	9	
TABLE	1	10	
Preliminary	Testing	11	
Prior	 to	 the	 assessment	 of	 aerobic	 capacity,	 anthropometric	 data	 was	 collected	 with	 body	 mass	12	
measured	using	digital	scales	(Adams	Equipment,	Model	GFK	150;	Milton	Keynes,	UK)	and	body	fat	13	
assessed	 from	 four	 sites	 (biceps,	 triceps,	 subscapular	 and	 supra-iliac)	 as	 described	 by	 Durnin	 and	14	
Womersley	 (1974)	 using	 skinfold	 callipers	 (Harpenden	 Instruments,	 UK).	 Participants	 then	15	
performed	a	standardised	stepwise	incremental	test	on	a	cycle	ergometer.	Cycling	started	at	80	W,	16	
increasing	by	24	W	each	minute,	as	previously	described	by	(Gibson	et	al.	2015).	17	
Experimental	design	18	
The	 outline	 of	 this	 single	 blind,	 randomised	 and	 controlled	 study	 is	 presented	 in	 Figure	 2.	19	
Participants	attended	the	laboratory	in	Eastbourne,	UK	(10	m	altitude)	on	an	individual	basis	on	four	20	
separate	 occasions;	 three	 involved	 resting	 in	 a	 hypoxic	 environment	 at	 three	 different	 levels	 of	21	
hypoxia	and	once	 in	normoxia.	Participants	were	required	to	attend	the	 laboratory	for	eight	and	a	22	
half	 hours	 for	 each	 visit.	 They	were	 instructed	 to	 eat	 the	 same	 breakfast	 before	 each	 visit,	 were	23	
supplied	with	 a	 standardised	 isocalorific	 lunch	 and	 drank	water	 ad	 libitum	 throughout	 the	 testing	24	
procedure.	The	order	of	the	trials	was	randomised,	determined	by	a	Latin	squares	design.	Each	trial	25	
was	separated	by	a	seven	day	wash	out	period	(MacKenzie	et	al.	2008).	All	trials	commenced	at	the	26	
same	time	for	each	individual	participant	between	07:30	and	09:30,	to	control	for	diurnal	variations	27	
in	EPO	(Klausen	et	al.	1993;	Klausen	et	al.	1996).	28	
FIGURE	2	29	
Hypoxic	Exposures	30	
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Following	 a	 15	 min	 resting	 period	 at	 sea	 level,	 during	 which	 baseline	 measures	 were	 recorded,	1	
participants	 spent	 two	hours	 resting	 in	 a	normobaric	hypoxic	 chamber	achieved	using	a	purposed	2	
built	nitrogen-enriched	chamber	(Altitude	Centre;	London,	UK),	at	four	different	simulated	altitudes	3	
[FiO2:	0.209,	(SL),	FiO2:	0.135,	(3,600	m),	FiO2:	0.125,	(4,200	m)	and	FiO2:	0.115,	(4,800	m)].	Oxygen	4	
concentration	 was	 monitored	 and	 adjusted	 continually	 by	 automated	 computer	 feedback.	5	
Participants	 remained	 seated	 during	 the	 two	 hours	 exposure.	 The	 laboratory	 environmental	6	
conditions	[temperature	=	22.8	±	0.7°C,	relative	humidity	=	38.4	±	1.8%,	pressure	=	760	±	2mmHg,	7	
FiCO2	 (range)	 =	 0.05	 –	 0.1%]	 were	 maintained	 stable	 throughout.	 For	 the	 remaining	 six	 hours,	8	
participants	rested	in	normoxic	conditions	in	temperate	laboratory	conditions.	9	
FiO2	was	measured	in	the	chamber	every	15	minutes.		SpO2	was	measured	every	15	minutes,	should	10	
a	participant	remain	below	70%	they	were	removed	from	the	chamber	(zero	 incidences).	The	Lake	11	
Louise	Questionnaire	was	also	completed	every	30	mins	to	assess	for	symptoms	off	acute	mountain	12	
sickness	 (AMS),	 should	a	participant	 remain	at	6	or	above.	They	were	 removed	 from	the	chamber	13	
(zero	incidences).	14	
Preliminary	Measures	15	
Upon	arrival	participants	weighed	themselves	(SECA	778;	SECA	UK,	Birmingham,	UK)	and	provided	a	16	
urine	 sample.	 Urine	 specific	 gravity	 (Uspg)	 was	 assessed	 using	 a	 refractometer	 (Atago,	 USA)	 and	17	
urine	 osmolality	 (Uosm)	 was	 measured	 using	 an	 osmometer	 (Osmocheck;	 Vitech	 Scientific,	 West	18	
Sussex,	UK).	Euhydration	was	achieved	when	urine	osmolality	and	urine	specific	gravity	were	below	19	
700	 mOsmol.kg-1	 H2O	 and	 1.020,	 respectively	 (Sawka	 et	 al.	 2007).	 Participants	 were	 required	 to	20	
consume	500	ml	of	water	and	wait	30	min	before	they	entered	the	chamber	if	they	were	above	the	21	
criteria	(MacKenzie	et	al.	2008).	Participants	then	sat	and	rested	for	15	minutes	for	a	resting	heart	22	
rate	(HR)	and	O2	saturation	(SpO2)	to	be	measured	prior	to	entering	the	chamber.	23	
Physiological	measures	24	
Heart	rate	(Polar	810i	heart	rate	monitor;	Kempele,	Finland)	and	SpO2	(Nonin	2500;	Nonin	Medical	25	
Inc,	Minesota,	USA)	were	measured	every	15	min	whilst	 in	the	hypoxic	chamber	and	every	30	min	26	
outside	of	the	chamber.	The	measurement	was	recorded	after	30	seconds.	27	
Haematological	measures	28	
For	venous	blood	sampling	a	cannula	(18G	x	1.5"	BD	Venflon	I.V.	Cannula;	BD	Infusion	Therapy	AB,	29	
Helingborg,	 Sweden)	 was	 positioned	 in	 the	 anticubital	 fossa.	 Blood	 samples	 were	 taken	 before	30	
entering	 the	 chamber,	 after	 one	 and	 two	 hours	 whilst	 in	 the	 chamber	 and	 at	 four,	 six	 and	 eight	31	
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hours	outside	the	chamber.	After	discarding	the	first	1	ml,	venous	blood	was	collected	(~8	ml)	with	a	1	
plastic	syringe	(10	ml	BD	Plastipak;	Becton	&	Dickinson	UK,	Oxford,	UK)	and	dispensed	into	two	5ml	2	
K-EDTA	collection	tubes	(Sarstedt	Ltd.,	Leicester,	UK)	prior	to	centrifugation	at	2,200	rpm	(Eppendorf	3	
Refrigerated	 Centrifuge	Model	 5702R;	 Eppendorf	 UK	 Ltd.,	 Stevenage,	 UK)	 for	 15	min	 to	 separate	4	
plasma.	Plasma	was	pipetted	 (Eppendorf	Research/Research	Pro)	 into	1.5	ml	microtubes	 (Western	5	
Laboratory	 Service,	 Hampshire,	 UK)	 and	 stored	 at	 a	 -85°C	 (Sanyo	 VIP	 Series;	 Sanyo	 Electric	6	
Biomedical	Co,	Ltd.,	Japan)	until	the	samples	were	analysed.	7	
[EPO],	IL-6	and	TNFα	concentrations	were	measured	in	plasma	for	all	four	trials	(SL,	3,600	m,	4,200	8	
m,	and	4.800	m).	Enzyme-linked	immunosorbent	assays	were	used	in	accordance	with	manufacturer	9	
instructions	to	determine	concentrations	for	[EPO]	(Roche	Diagnostics	Ltd.,	Lewes,	UK)	and	for	IL-6	10	
and	TNFα	(DuoSet	ELISA	Development	System;	R&D	Systems	Inc.,	Abingdon,	UK).	The	technical	error	11	
of	measurement	(TEM)	between	duplicate	samples	for	[EPO]	was	3.8%,	with	a	unit	error	value	of	0.7	12	
mUmL-1,	for	IL-6	it	was	7.1%,	with	a	unit	error	value	of	2.76	pgmL-1	and	for	TNFα	it	was	4.1%,	with	a	13	
unit	error	value	of	518.7	pgmL-1.	14	
Statistical	Analysis	15	
Data	was	assessed	for	normality	and	sphericity	and	adjusted	where	necessary	using	the	Huynh-Feldt	16	
method.	Differences	in	[EPO],	IL-6	and	TNFα	at	each	time	point	(e.g.	Pre,	1h,	2h,	4h,6h	and	8h.),	HR	17	
and	 SpO2	 were	 analysed	 with	 a	 two-way	 repeated	 measures	 ANOVA	 (hypoxia	 x	 time),	 with	18	
Bonferroni	 correction	 used	 to	 determine	 differences	 between	 groups.	 For	 statistical	 analysis	 SpO2	19	
and	HR	measurements	were	averaged	for	each	hour	in	the	chamber	and	every	two	hours	outside	of	20	
the	chamber.	Typical	error	of	measurement	(TEM)	calculations	were	carried	out	on	duplicate	[EPO],	21	
IL-6	and	TNFα	 samples	using	a	method	previously	described	by	 (Hopkins	2000).	All	 statistical	 tests	22	
were	completed	using	SPSS	Statistics	22	(International	Business	Machines	Corp.,	Armonk,	New	York).	23	
Significance	was	accepted	at	P	<	0.05.	Values	are	reported	as	mean	±	SD	unless	otherwise	indicated.	24	
Effect	sizes	for	main	effects	and	interactions	are	presented	as	partial	eta	squared	(ηp2)	in	accordance	25	
with	Lakens	(2013).	 	26	
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Results	1	
Physiological	Measures	2	
There	was	an	effect	on	SpO2	over	time	(F	=	927.298,	P	=	0.001,	ηp2	=	0.99),	in	hypoxia	(F	=	258.717,	P	3	
=	0.001,	ηp2	=	0.97)	and	an	 interaction	effect	between	time*hypoxia	 (F	=	156.411,	P	=	0.001,	ηp2	=	4	
0.96).	Bonferroni	comparison	identified	significant	differences	between	Pre	and	1h/2h,	respectively,	5	
at	 3,600	 m	 (P	 =	 0.001),	 4,200	 m	 (P	 =	 0.001)	 and	 4,800	 m	 (P	 =	 0.001).	 Between	 trials	 significant	6	
differences	in	SpO2	were	found	at	1h	(P	=	0.001)	and	2h	(P	=	0.001)	between	SL	(98	±	0	and	98	±	1%),	7	
3,600	m	(87	±	2	and	87	±	3%),	4,200	m	(83	±	1	and	83	±	1%)	and	4,800	m	(76	±	2	and	75	±	3%).	No	8	
differences	were	 found	at	any	point	at	SL	 (P	=	1.000)	and	no	differences	were	 found	between	Pre	9	
and	4h,	6h	or	8h	at	3,600	m,	4,200	m	or	4,800	m.	Post-hoc	data	is	presented	in	figure	3A.		10	
There	was	an	effect	on	HR	over	time	(F	=	21.294,	P	=	0.001,	ηp2	=	0.75),	in	hypoxia	(F	=	11.739,	P	=	11	
0.001,	ηp2	=	0.63)	and	an	interaction	effect	between	time*hypoxia	(F	=	9.837,	P	=	0.001,	ηp2	=	0.59).	12	
Bonferroni	comparison	identified	significant	differences	(P	=	0.022)	between	mean	HR	at	SL	(57	±	7	13	
bmin-1)	 and	4,800	 (65	 ±	 10	bmin-1).	 At	 SL	 no	differences	 (P	 >	 0.05)	were	observed	over	 time.	At	14	
4,200	m	and	4,800	m	HR	at	was	significantly	higher	(P	<	0.05)	at	1h	(66	±	5	and	75	±	8	bmin-1)	and	2h	15	
(63	±	6	and	72	±	10	bmin-1),	respectively,	compared	to	4h	(58	±	4	and	61	±	9	bmin-1),	6h	(58	±	6	and	16	
60	±	7	bmin-1)	and	8h	during	(55	±	8	and	58	±	9	bmin-1).	Post-hoc	data	is	presented	in	figure	3B.	17	
FIGURE	3A/B	18	
Haematological	Measures	19	
An	effect	on	[EPO]	was	observed	over	time	(F	=	9.959,	P	=	0.001,	ηp2	=	0.59).	Mean	[EPO]	peaked	at	20	
4h	in	3,600	m,	in	4,200	m	and	in	4,800	m.	No	differences	were	observed	in	[EPO]	from	pre-hypoxia	21	
(5.36	 ±	 1.61	 mUmL-1)	 to	 8h	 (6.4	 ±	 1.45	 mUmL-1)	 during	 the	 SL	 trial.	 Bonferroni	 comparison	22	
identified	a	difference	in	[EPO]	between	Pre	and	4h	at	4,200	m	(P	=	0.009)	and	at	4,800m	(P	=	0.037),	23	
but	not	at	3,600	m	 (P	 =	1.000).	 There	was	no	main	effect	 for	hypoxia	 (F	=	 0.359,	P	=	 0.704,	ηp2	 =	24	
0.05),	 nor	 an	 interaction	 effect	 between	 time*hypoxia	 (F	 =	 1.296,	P	 =	 0.250,	 ηp2	 =	 0.16).	 Figure	 4	25	
illustrates	the	response	of	plasma	[EPO]	during	each	hypoxic	trial.		26	
FIGURE	4	27	
No	effect	on	IL-6	was	found	over	time	(F	=	0.683	P	=	0.547,	ηp2	=	0.09),	simulated	hypoxia	(F	=	0.242,	28	
P	=	 0.789,	 ηp2	 =	 0.03),	 or	 an	 interaction	 effect	 between	 time*hypoxia	 (F	 =	 0.465,	P	=	 0.907,	 ηp2	 =	29	
0.06).	Figure	5	illustrates	the	response	of	plasma	IL-6	during	each	hypoxic	trial.	30	
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FIGURE	5	1	
There	was	also	no	effect	on	TNFα	found	over	 time	(F	=	1.748,	P	=	0.1.82,	ηp2	=	0.20),	hypoxia	 (F	=	2	
0.945,	P	=	0.412,	ηp2	=	0.12),	or	an	interaction	effect	between	time*hypoxia	(F	=	1.545,	P	=	0.142,	ηp2	3	
=	0.18).	Figure	6	illustrates	the	response	of	plasma	TNFα	during	each	hypoxic	trial.	4	
FIGURE	6	5	
	6	
TABLE	2	7	
Relationship	between	peak	[EPO]	and	other	measures	8	
No	correlation	(P	>0.05)	was	found	between	desaturation	during	hypoxic	exposure	and	peak	Δ[EPO]	9	
(r	=	 -0.106)	across	all	 three	hypoxic	 trails	 (see	Fig	7A).	Further	 to	 this	no	correlation	 (P	>0.05)	was	10	
found	between	peak	Δ[EPO]	and	baseline	IL-6	(r	=	0.140)	(see	Fig	7B),	and	also	between	peak	Δ[EPO]	11	
and	baseline	TNFα	(r	=	0.159)	(see	Fig	7C).	12	
FIGURE	7	A/B/C	 	13	
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Discussion	1	
The	novel	findings	of	this	study	were	that	a	normobaric	hypoxic	exposure	of	two	hours	at	an	FiO2	of	2	
<0.125	(>4,200	m)	are	sufficient	to	increase	EPO	production,	which	peaked	2h	post-exposure	and	are	3	
maintained	 up	 to	 4h	 post-exposure.	 Despite	 observing	 a	 greater	 increase	 in	 [EPO]	 as	 a	 result	 of	4	
increased	severity	of	hypoxia,	large	individual	variability	(see	Table	2)	between	participants	resulted	5	
in	 no	main	 effect	 from	hypoxia	 itself.	 All	 [EPO]	 returned	 to	 baseline	 levels	 6h	 post-exposure.	 The	6	
present	study	also	found	that	there	was	no	relationship	between	baseline	 IL-6	and	TNFα	and	peak	7	
Δ[EPO].	 There	were	 also	 no	differences	 in	 IL-6	 and	 TNFα	production	 as	 a	 result	 of	 three	different	8	
simulated	altitudes.	9	
EPO	response	to	normobaric	hypoxia	10	
Figure	1	 illustrates	the	results	of	 the	previous	 investigation	 into	acute	hypoxic	exposures	and	EPO.	11	
The	 present	 invesigation	 found	 that	 two	hours	 of	 normobaric	 hypoxia	 at	 FiO2:	~0.135	 	 (3,600	m),	12	
FiO2:	 ~0.125	 (4,200	m)	 and	 FiO2:	 ~0.115	 (4,800	m)	 caused	 an	 increase	 in	 [EPO]	 of	 22%	 (range:	 -13	
16―53%),	 43%	 (range:	 14―100%)	 and	 52%	 (range:	 16―113%),	 respectively,	 peaking	 two	 hours	14	
post-exposure,	maintaining	until	four	hours	and	returning	to	baseline	after	six	hours.	Knaupp	et	al.	15	
(1992)	revealed	that	two	hours	of	normobaric	hypoxia	at	~5,500	m	elicited	a	~50%	increase	in	[EPO]	16	
and	Ge	et	al.	(2002)	also	found	an	increase	of	~50%	in	[EPO]	after	24	hours	of	hypobaric	hypoxia	at	17	
~2,500-2,800	 m.	 For	 the	 application	 of	 a	 hypoxic	 exposure	 on	 return	 to	 sea	 level	 post-altitude	18	
training	 camp,	 normobaric	 hypoxia	 is	 the	 most	 accesible	 option,	 at	 a	 moderate	 to	 high-altitude	19	
(<4,000	m),	and	at	a	short	enough	duration	that	it	would	fit	into	an	athletes	daily	training	schedule	20	
(<2	h).		21	
FIGURE	8	22	
Chronically	increased	EPO	synthesis	leads	to	a	progressive	increase	in	tHbmass	(Lundby	et	al.	2007),	23	
however,	hypoxia-induced	changes	 in	EPO	release	seem	to	be	subject	 to	a	marked	 inter-individual	24	
variability	(Chapman	et	al.	1998).	This	may	explain	why	there	is	a	varied	athlete	response	in	tHbmass	25	
to	altitude	training	camps	(Mclean	et	al.	2013).	In	our	study	despite	a	greater	reduction	in	SpO2	from	26	
an	increased	severity	of	hypoxia	causing	a	greater	production	in	[EPO],	 individuals	who	were	more	27	
O2	 desaturated	 did	 not	 always	 produce	 a	 greater	 [EPO]	 (see	 Fig	 7).	 As	 such,	 the	 finding	 are	 in	28	
agreement	with	previous	 literature	 (Ge	et	al.	2002;	Friedmann	et	al.	2005;	MacKenzie	et	al.	2008)	29	
who	 also	 found	 a	marked	 individual	 variability	 in	 EPO	 release	 at	 different	 altitudes.	 Although	 the	30	
participants	in	the	present	study	were	well-trained,	similar	value	and	variations	of	[EPO]	have	been	31	
reported	in	elite	athletes	(Clark	et	al.	2009;	Garvican	et	al.	2012;	Pottgiesser	et	al.	2012).	32	
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The	exact	mechanisms	for	individual	variability	in	EPO	response	to	altitude	are	not	well	determined	1	
(Fudge	et	al.	2012).	Chapman	et	al.	(2010)	found	that	there	was	no	correlation	between	changes	in	2	
EPO	at	altitude	and	hypoxic	ventilatory	response	measured	at	sea	 level;	suggesting	that	peripheral	3	
chemoresponsiveness	 may	 not	 be	 responsible	 for	 the	 variability	 in	 EPO	 response,	 and	 the	 likely	4	
mechanisms	may	be	downstream	from	the	lung.	Ge	et	al.	(2002),	however,	believed	EPO	production	5	
at	 altitude	 is	 governed	 by	 “upstream”	 factors	 related	 to	 renal	 parenchymal	 PO2,	 as	well	 as	 other	6	
undetermined	 mechanisms,	 possibly	 related	 to	 transcriptional	 regulation	 of	 EPO	 by	 renal	 tissue	7	
hypoxia.	Alternatively,	 pro-inflammatory	 cytokines	have	been	 shown	 to	 trigger	 the	 suppression	of	8	
renal	EPO	production	and	therefore	erythropoiesis	(Morceau	et	al.	2009),	with	the	inhibition	of	EPO	9	
production	 shown	 in	 vitro	 and	 in	 vivo	 to	 potentially	 involve	 IL-1,	 IL-6,	 and	 TNFα	 (Morceau	 et	 al.	10	
2009).	However,	the	present	study	found	that	baseline	IL-6	and	TNFα	did	not	correlate	with	the	peak	11	
Δ[EPO]	 and	 there	 were	 no	 differences	 in	 IL-6	 and	 TNFα	 production	 as	 a	 result	 of	 three	 different	12	
levels	of	hypoxia.	13	
The	 present	 investigation	 found	 no	 relationship	 between	 ΔSpO2	 and	 peak	 Δ[EPO]	 percentage.	14	
MacKenzie	 et	 al.	 (2008)	 suggested	 EPO	 production	 is	 noticeably	 augmented	 by	 the	 depression	 of	15	
arterial	O2	content	 (CaO2),	as	a	 result	of	decreases	 in	SpO2.	Therefore,	a	greater	 reduction	 in	SpO2	16	
combined	with	 an	 inability	 to	 increase	 HVR	 could	 facilitate	 a	 greater	 secretion	 of	 EPO	 (Jelkmann	17	
1992).	Ge	et	al.	 (2002)	also	 suggested	 that	 the	mechanism	of	an	 individual	 response	 to	altitude	 is	18	
likely	 to	 include	 the	greater	oxyhemoglobin	desaturation.	This	occurs	as	 the	PO2	 falls	 to	 the	 steep	19	
portion	of	the	oxyhemoglobin	dissociation	curve	and,	therefore	changes	in	SpO2	are	mirrored	by	EPO	20	
levels	at	all	altitudes.	The	investigations	by	Ge	et	al.	(2002)	and	MacKenzie	et	al.	(2008)	only	found	a	21	
moderate	relationship	between	ΔCaO2/ΔSpO2	and	changes	in	EPO.		22	
Inflammatory	response	to	normobaric	hypoxia		23	
Hypoxia	 and	 inflammation	 are	 interrelated	 at	molecular,	 cellular,	 and	 clinical	 levels	 (Eltzschig	 and	24	
Carmeliet	 2011).	 Oxidative	 stress	 and	 the	 release	 of	 pro-inflammatory	 cytokines	 (e.g.,	 IL-1,	 IL-6,	25	
TNFα),	which	are	systemic	inflammatory	markers,	are	associated	with	acute	hypoxia	closely	and	are	26	
proportional	to	the	severity	of	hypoxia	(He	et	al.	2014).	Previously,	Klausen	et	al.	(1997)	found	that	27	
after	1	day	at	4,350	m,	there	was	a	non-significant	change	in	serum	IL-6		by	56%	and	by	day	4	had	28	
significantly	increased	by	86%,	however,	there	were	no	changes	in	IL-1	or	TNFα.	The	increase	in	IL-6	29	
was	 significantly	 correlated	 (r	 =	 -0.45)	 with	 hypoxemia	 (mean	 SpO2:	 79-83%),	 but	 not	 HR	 or	30	
symptoms	 of	 AMS.	 The	 authors	 suggested	 that	 the	 increase	 of	 serum	 IL-6	 was	 not	 secondary	 to	31	
increased	sympathetic	nervous	activity	or	general	distress	during	altitude	acclimatisation	due	to	the	32	
lack	of	relation	between	serum	IL-6	and	heart	rates	or	AMS	scores.		33	
11	
	
The	present	investigation	found	that	baseline	levels	of	IL-6	and	TNFα	did	not	inhibit	the	production	1	
of	 EPO	 (See	 Fig.	 7B/C).	 Furthermore,	 there	were	no	difference	 in	 IL-6	 and	TNFα	at	 three	 levels	of	2	
normobaric	 hypoxia,	 despite	 increases	 in	HR	 and	decreases	 in	 SpO2. Jelkmann	 et	 al.	 (1992)	 found	3	
that	the	addition	of	IL-1	and	TNFα	inhibited	the	production	of	EPO	in	hypoxic	human	hepatoma	cell	4	
cultures,	 however,	 inhibition	 did	 not	 occur	 with	 introduction	 of	 IL-6,	 thus	 believing	 that	 IL-1	 and	5	
TNFα	have	been	shown	to	affect	gene	expression	in	human	hepatoma	cultures	at	the	transcriptional	6	
level	(Jelkmann	et	al.	1994).	The	authors	reported	that	IL-6	does	not	affect	EPO	production	in	vitro;	7	
moreover,	 IL-6	 appears	 to	 inhibit	 renal	 EPO	 formation.	 Inflammatory	 responses	 to	 hypoxia	 are	8	
complex	with	various	cytokines	both	inhibiting	and	preserving	the	production	of	EPO.	At	present	it	is	9	
not	clear	what	pro-inflammatory	cytokines	regulate	the	production	of	EPO,	but	in	this	investigation	10	
inflammation	did	compromise	endogenous	[EPO].	11	
Future	Directions	12	
Additional	normobaric	hypoxic	exposures	of	two	hours,	with	the	aim	of	increasing	the	production	of	13	
EPO,	have	not	been	implemented	on	return	to	sea-level	after	an	altitude	training	camp.	Rodríguez	et	14	
al.	 (2000)	 and	 Casas	 et	 al.	 (2000)	 exposed	 trained	 volunteers	 to	 hypobaric	 hypoxia	 at	 simulated	15	
altitudes	of	~4,000-5,000	m	for	90	minutes,	three	times	a	week	for	three	weeks.	This	stimulus	led	to	16	
an	effective	stimulation	of	erythropoietic	adaptations,	such	as,	significant	increases	in	red	blood	cell	17	
(RBC)	 count,	 [Hb]	 and	 reticulocytes.	 Katayama	 et	 al.	 (2003),	 however,	 utilised	 a	 similar	 protocol	18	
(4,500	m	for	two	hours,	three	times	a	week	for	three	weeks)	with	endurance	runners	and	found	no	19	
changes	 in	 haematological	 parameters,	 including	 [Hb],	 Hct,	 RBC	 count,	 reticulocytes	 or	 EPO.	 The	20	
large	 individual	 variation	 and	 differing	 populations	 used	 could	 account	 for	 these	 contradictory	21	
findings;	 nevertheless,	 the	 protocol	 should	 be	 tested	 post-altitude	 training	 camp	 alongside	22	
measurement	of	EPO	and	tHbmass.		23	
Further	 to	 this,	 tighter	 controls	 surrounding	 exhaustive	 exercise	 pre-hypoxic	 exposure	 should	 be	24	
considered,	as	different	types	of	exercise	(concentric,	eccentric,	submaximal,	maximal)	are	known	to	25	
cause	increases	in	pro-inflammatory	cytokines	(Pedersen	et	al.	1998;	Nieman	et	al.	2001;	Jürimäe	et	26	
al.	2011)	and	intense	exercise	provides	a	physiological	stimulus	to	increase	EPO	production	(Roberts	27	
and	Smith	1999).	Additional	modifications	to	the	protocol	could	include	blood	samples	12,	14	and	48	28	
hours	post-hypoxic	exposure	to	determine	if	there	is	a	delayed	increased	in	EPO	or	pro-inflammatory	29	
cytokines	 as	 has	 previously	 been	 suggested	 (Pedersen	 et	 al.	 1998;	 Ge	 et	 al.	 2002).	 The	 present	30	
investigation	did	control	 for	diurnal	variations	 in	haematological	markers	by	ensuring	that	all	 trials	31	
were	started	between	07:30	and	09:30	as	previous	research	has	shown	that	EPO	is	subject	to	distinct	32	
diurnal	 variation	 in	 trained	 and	 untrained	 individuals	 (Klausen	 et	 al.	 1993),	 as	 well	 as	 in	 both	33	
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normoxia	and	hypoxia	(Klausen	et	al.	1996).	Keramidas	et	al.	(2011)	observed	diurnal	variation	of	a	1	
nadir	 in	values	of	EPO	in	the	morning	hours,	and	zenith	 levels	during	the	evening	and	night	hours.	2	
Additional	 haematological	measurements	 prior	 to	 the	 experimental	 period	would	 provide	 a	more	3	
accurate	baseline	interpretation.	4	
Practical	Applications	5	
A	decrease	in	EPO	and	tHbmass	on	return	to	sea	level	has	been	observed	in	athletes	after	altitude	6	
training	 camps	 lasting	 3-4	 weeks	 (Heinicke	 et	 al.	 2005;	 Clark	 et	 al.	 2009;	 Garvican	 et	 al.	 2012;	7	
Pottgiesser	et	al.	2012).	When	red	cell	mass	exceeds	 the	physiological	 requirement	at	 the	altitude	8	
resided	 in,	 EPO	 secretion	 is	 suppressed	 (Rice	 and	 Alfrey	 2005)	 and	 a	 destruction	 in	 red	 cells,	 or	9	
neocytolysis,	occurs.	Athletes	who	are	acclimated	after	an	altitude	training	camp,	who	then	descend	10	
to	sea	level	to	compete	would	have	red	cell	mass	that	is	higher	than	necessary	for	homeostasis	their	11	
new	environment.	The	rapid	destruction	of	reticulocytes	and	the	decline	in	production	of	new	ones	12	
may	depend	on	a	drop	in	EPO	levels	(Alfrey	et	al.	1997).	Additionally,	EPO	not	only	regulates	red	cell	13	
mass	but	also	prolongs	its	survival	(Rice	et	al.	2001).	For	an	athlete	with	a	faster	than	normal	decline	14	
in	 tHbmass	 upon	 return	 to	 sea	 level	 competing	 as	 soon	 as	 possible	 may	 be	 the	 most	 beneficial	15	
strategy	 but	 this	 is	 not	 always	 logistically	 achievable.	 Additional	 hypoxic	 exposures	 have	 been	16	
suggested	as	strategy	to	prevent	the	sudden	drop	off	in	EPO	(Pottgiesser	et	al.	2012).	17	
An	 athlete’s	 busy	 travel	 schedule,	 external	 commitments	 and	 competition	 programme,	 make	 it	18	
difficult	 to	 time	 competing	 at	 sea	 level	 after	 an	 altitude	 training	 camp.	 Chapman	 et	 al.	 (2013b),	19	
suggested	that	if	an	athlete	completes	a	4	week	altitude	training	camp,	followed	by	a	short	time	(~7-20	
14	days)	at	sea	level	to	compete,	returning	to	altitude	even	for	a	short	time	may	mitigate	or	delay	21	
the	effects	of	neocytolysis	by	re-establishing	EPO	levels,	although	this	has	not	been	proven.	This	 is	22	
not	 for	 added	 erythropoiesis,	 as	 is	 typically	 done	 with	 altitude	 residence,	 but	 more	 to	 delay	 the	23	
selective	destruction	of	reticulocytes	due	to	 lower	than	baseline	EPO	concentrations,	as	a	result	of	24	
the	 athlete	 just	 remaining	 at	 sea	 level.	 By	 keeping	 EPO	 elevated,	 in	 addition	 to	 preventing	25	
neocytolysis,	exercise	performance	might	be	improved	(Schuler	et	al.	2012;	Durussel	et	al.	2013).		26	
Perspectives	27	
In	 Caucasian	 populations	 erythropoiesis	 is	 a	 key	 acclimatization	 response	 that	 increases	 the	 O2-28	
carrying	capacity	of	the	blood,	i.e.	tHbmass,	as	a	result	of	chronic	exposure	to	altitude	(Chapman	et	29	
al.	 2013).	 A	 change	 in	 tHbmass	 by	 1	 g	 causes	 a	 change	 in	 V"O2max	 by	 approximately	 4	 mlmin-1	30	
(Schmidt	and	Prommer	2010),	for	an	athlete	increased	blood	gas	storage	capacity	is	very	important,	31	
therefore,	 the	maintenance	 of	 tHbmass	 should	 be	 considered.	 Chapman	 et	 al.	 (2014)	 stated	 that	32	
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brief,	 short-term	 periods	 of	 normobaric	 hypoxia	may	 provide	 a	 sufficient	 stimulus	 to	 significantly	1	
increase	 EPO,	 despite	 this	 not	 being	 enough	 to	 accelerate	 erythropoiesis	 itself.	 These	 exposures	2	
could	take	place	during	the	day,	around	the	athlete	training	schedule,	to	preserve	the	hematologic	3	
acclimatization	response	for	a	longer	time,	thereby	expanding	the	window	for	optimal	competition.	4	
The	increases	 in	[EPO]	found	in	the	current	 investigation	indicate	that	a	normobaric	hypoxic	 ‘dose’	5	
(i.e.,	FiO2	~0.125-0.115,	equivalent	 to	4,200	m	and	above,	 for	 two	hours)	may	prevent	 the	sudden	6	
drop	 in	 EPO	 that	 has	 been	 shown	 post-altitude	 and,	 therefore,	 maintain	 any	 enhancements	 in	7	
tHbmass.	 The	 release	 of	 EPO	 is	 subject	 to	 a	 distinct	 inter-individual	 variation	 that	 can	 only	 be	8	
partially	 explained	 by	 reductions	 in	 oxyhaemoglobin	 saturation	 but	 is	 not	 effected	 by	 systemic	9	
markers	of	inflammation.	 	10	
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Tables	1	
Table	1:	Participant	anthropometric	characteristics	and	baseline	haematological	values		2	
Characteristics	 	
Age	(years)	 27	±	4	
Stature	(cm)	 179	±	6	
Body	Mass	(kg)	 77.5	±	9.0	
Body	Fat	(%)	 13.1	±	2.5	
VO2max	(mlkgmin-1)		 50.9	±	8.2	
[EPO]	(mUml-1)	 5.95	±	1.51	
IL-6	(pgml-1)	 8.86	±	7.17	
TNFα	(pgml-1)	 3095.6	±	3934.9	
	3	
	4	
20	
	
Table	2:		Haematological	data	measured	pre-hypoxia,	during	hypoxia	(1h	and	2h)	and	post-hypoxia	(4h,	6h	and	8h).	1	
	 	 Pre	 1h	 2h	 4h	 6h	 8h	
[EPO]	
(mUml-1)	
3,600	m	 6.54	±	3.54	 	6.48	±	1.33	 6.34	±	1.17	 7.61	±	1.45	 7.52	±	1.63	 7.31	±	1.96	
4,200	m	 5.86	±	1.48	 5.93	±	1.48	 7.29	±	1.84	 8.06	±	1.47	 7.96	±	3.06	 6.81	±	2.78	
4,800	m	 6.04	±	1.40	 6.07	±	1.57	 6.69	±	1.40	 8.94	±	2.01	 8.85	±	2.75	 7.50	±	3.11	
Il-6	
(pgml-1)	
3,600	m	 8.91	±	8.12	 9.38	±	7.84	 9.52	±	9.16	 9.27	±	8.86	 9.64	±	7.36	 10.44	±	8.41	
4,200	m	 9.82	±	8.14	 9.11	±	9.07	 10.42	±	11.36	 9.20	±	8.56	 8.68	±	7.55	 9.03	±	7.63	
4,800	m	 8.99	±	7.37	 8.50	±	6.11	 9.34	±	7.89	 7.85	±	5.68	 8.70	±	6.59	 9.79	±	7.57	
TNFα	
(pgml-1)	
3,600	m	 2766.3	±	3625.8	 3113.2	±	4276.7	 3739.8	±	5145.9	 3397.7	±	4539.1	 3105.4	±	4227.8	 3189.9	±	4198.0	
4,200	m	 3372.2	±	4701.6	 3211.4	±	4528.6	 3088.1	±	4379.5	 2905.3	±	3838.5	 2992.5	±	4090.2	 3317.3	±	4443.0	
4,800	m	 3132.6	±	4144.4	 3213.8	±	4110.6	 3165.2	±	3916.5	 3399.0	±	4646.5	 3278.6	±	4650.5	 3154.6	±	4553.2	
	2	
	3	
21	
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Figures	1	
	2	
		3	
Figure	1:	EPO	response	to	hypoxic	exposure	duration	and	simulated	altitude.	The	different	bubbles	4	
represent	 the	 magnitude	 of	 increase	 in	 EPO	 as	 a	 result	 of	 hypoxic	 exposures.	 Different	 patterns	5	
within	bubble	indicate	different	investigations		6	
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	1	
TESTING DAY 
    Exposure             
 Pre  1h  2h  4h  6h  8h 
                  
                  
 
  
 
 
               
                  
 S1  S2  S3  S4  S5  S6 
                  
REST 
20.9% O2 
Either: 
SL GROUP (20.9% O2) 
3,600 m GROUP (13.5% O2)  
4,200 m GROUP (12.5% O2)  
4,800 m GROUP (11.5% O2) 
REST 
20.9% O2 
	2	
Figure	2:	Schematic	representation	of	the	study	outline.	(S	=	blood	sample)	3	
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	1	
		2	
Figure	3:	Difference	in	arterial	oxyhaemoglobin	saturation	(SpO2;	A)	and	heart	rate	(HR;	B)	after	two	3	
hours	simulated	hypoxia	at	SL,	3,600	m,	4,200	m	and	4,800	m.	Values	are	means	±	SD.	(†	P	≤	0.05	4	
denotes	 differences	 from	 Pre,	 	 ‡	 P	 ≤	 0.05	 denotes	 differences	 from	 1h	 and	 *	 P	 ≤	 0.05	 denotes	5	
differences	from	2	h).	Note	3,600	m	and	4,200	m	error	bars	removed	for	clarity.		 	6	
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	1	
Figure	4:	 	Percentage	differences	 from	baseline	 in	erythropoietin	concentration	 (Δ	 [EPO])	of	blood	2	
plasma	after	two	hours	at	simulated	altitudes	of	sea	level,	3,600	m,	4,200	m	and	4,800	m.	Values	are	3	
means	±	SD.	(†	P	≤	0.05	denotes	differences	from	Pre,		‡	P	≤	0.05	denotes	differences	from	1h	and	*	4	
P	≤	0.05	denotes	differences	from	2	h).	Note	4,200	m	error	bars	removed	for	clarity.	5	
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	2	
Figure	5:	 	Percentage	differences	 from	baseline	 in	 interleukin-6	 (Δ	 IL-6)	of	blood	plasma	after	 two	3	
hours	at	simulated	altitudes	of	sea	level,	3,600	m,	4,200	m	and	4,800	m.		4	
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Figure	 6:	 	 Percentage	 differences	 from	 baseline	 in	 tumor	 necrosis	 factor	 alpha	 (ΔTNFα)	 of	 blood	3	
plasma	after	two	hours	at	simulated	altitudes	of	sea	level,	3,600	m,	4,200	m	and	4,800	m.	4	
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	1	
	Figure	 7:	 Relationship	 between	 the	 degree	 of	2	
desaturation	 averaged	 over	 the	 2	 hours	 of	3	
simulated	 hypoxia	 (A);	 baseline	 IL-6	 (B);	4	
baseline	 TNFα	 (C)	 and	 the	 percentage	5	
difference	 of	 the	 peak	 in	 [EPO]	 during	 each	6	
hypoxic	 condition.	 As	 a	 group,	 there	 was	 no	7	
correlation	 between	 any	 of	 the	 variables	 and	8	
Peak	Δ	[EPO].		9	
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